<DOC>
	<DOCNO>NCT02835508</DOCNO>
	<brief_summary>The purpose study assess safety Pharmacokinetic ( PK ) profile JNJ-56021927 active metabolite JNJ-56142060 single-dose administration 60 milligram ( mg ) , 120 mg , 240 mg JNJ-56021927 tablet formulation healthy male Japanese participant .</brief_summary>
	<brief_title>Pharmacokinetic Study JNJ-56021927 When Taken Orally Tablet Formulation Healthy Male Japanese Participants</brief_title>
	<detailed_description />
	<criteria>Participant must body mass index 18.0 29.9 Kilogram per meter square ( kg/m^2 ) , inclusive , body weight less 50 Kilogram ( kg ) Participant must blood pressure 90 140 Millimeters Mercury ( mm Hg ) systolic , inclusive , high 90 mm Hg diastolic screening Participant must normal 12lead Electrocardiogram ( ECG ) ( base mean value triplicate parameter ) consistent normal cardiac conduction function screening , include : ) normal sinus rhythm ( heart rate 45 90 beat per minute , extremes include ) ; b ) QT interval correct heart rate accord Fridericia ( QTcF ) &lt; = 450 millisecond ( m ) ; c ) QRS interval less equal ( &lt; = ) 110 m ; ) PR interval &lt; 200 m ; e ) ECG morphology consistent healthy cardiac conduction function Participant must healthy Japanese male Participant must agree use adequate contraception method deem appropriate investigator ; always use condom intercourse donate sperm study 3 month study drug administration Participant history current clinically significant medical illness include ( limited ) cardiac arrhythmia cardiac disease , hematologic disease , coagulation disorder ( include abnormal bleeding blood dyscrasia ) , lipid abnormality , significant pulmonary disease , include bronchospastic respiratory disease , diabetes mellitus , hepatic renal insufficiency , thyroid disease , neurologic psychiatric disease , infection , illness investigator considers exclude participant could interfere interpretation study result Participant donate blood blood product substantial loss blood 200 milliliter ( mL ) within 1 month study drug administration , great equal ( &gt; = ) 400 mL within 3 month study drug administration , participant donate total volume blood past one year exceed 1200 mL , participant intention donate blood blood product study least 2 month completion study Participant presence sexual dysfunction ( abnormal libido , erectile dysfunction , etc ) medical condition would affect sexual function Participant receive investigational drug include investigational vaccine use invasive investigational medical device within 3 month within period le 10 time drug 's halflife , whichever longer , plan study drug administration Participant history hepatitis B surface antigen ( HBsAg ) hepatitis C antibody ( antihepatitis C virus { HCV } ) positive , clinically active liver disease , test positive HBsAg antiHCV screen</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>